

ABOUT OUR REPORT

Clinical Research Malaysia (CRM) is proud to share our achievements and success stories in this 2020 Annual Report. We encourage our stakeholders, industry partners, investigators and members of the community to take a moment to read our 5th annual report, which contains information about the important work that our organisation does to build a comprehensive research ecosystem in Malaysia.

For industry sponsors, the success of a sponsored research depends upon choosing the right country to conduct clinical trials. Speed, quality and reliability are essential criteria for a site to be awarded the study. Malaysia offers a compelling package to sponsors and contract research organisations (CROs) when it comes to conducting sponsored research.

Simply put, a very strong emphasis on patient safety and benefit is combined with a well-developed and equipped healthcare system that is manned by well-trained, highly qualified and English literate medical professionals. Moreover, Malaysia's multi-ethnic population provides sponsors and CROs with access to genetic diversity while the costs of conducting clinical trials are very competitive when compared to neighbouring countries in the region.

The long-term focus by the Malaysian Government is to make Malaysia a significant global player in clinical research and this is made possible through the establishment of CRM. CRM provides advance global health solutions for a brighter, more hopeful future for the people by providing speedy and reliable end-to-end clinical research support. CRM works together with its partners to create an impetus in delivering better services to its end clients and at the same time creating high-skilled job opportunities.

In this annual report, we will highlight CRM's milestones to showcase Malaysia's potential as the preferred hub for conducting clinical trials.

INSIDE THIS REPORT

ABOUT OUR REPORT	2
FOREWORD	4
BOARD OF DIRECTORS	5
ORGANISATION CHART	6
ABOUT CRM	7
Our Vision & Mission	7
CRM's Core Services	7
Our Core Values	7
PERFORMANCE OVERVIEW	8
KPI Scorecard	8
CRM's Financial Performance	8
Recruitment & Study Coordinator Performance	9
Sponsored Research in Malaysia	9
Classification of Clinical Trials	10
Top Sites according to Therapeutic Areas in 2020	13
Site Recruitment Achievement in 2020	14
CRM Sponsored Research Awards	15
Feasibility Study Report	16
Sponsors & CROs	18
Placement & Growth of Study Coordinators	19
COVID-19 IN MALAYSIA	20
CRM ACTIVITIES 2020	21
CRM NEWS COVERAGE	24
PUBLICATIONS	25
CRM IN PHOTOS	27
WHAT'S NEXT IN 2021	30

FOREWORD



The year 2020 has presented us with many opportunities and challenges that was brought about by the COVID-19 pandemic. It has been a tough year for everyone, and CRM was no different. This was the second year that CRM was in self-sustaining mode without government funding, and the need to achieve the organization's formation objective of RM578 million in Gross National Income (GNI). Alhamdulillah, I am glad to announce that we managed to achieve a cumulative GNI of RM 608.4 million by the end of 2020, and as icing on the cake, the company has exceeded in its income generation with gross profit surplus of over RM600k, the first since its establishment in the year 2012.

This achievement would not be made possible without the continuous commitment from the clinical research industry who have played their part in bringing in more sponsored research into the country, propelling the growth of the clinical research market and providing access to innovative treatment and drugs to Malaysians.

The COVID-19 pandemic has also provided opportunities for the country to be involved in COVID-19 related research and CRM played an important role in COVID-19 vaccine discussion through science diplomacy and inter-ministerial engagements. While the impact of the pandemic in terms of patient recruitment are like the rest of Asia, Europe and the United States, the recovery on the recruitment rate was seen to be much faster and many essential clinical studies resume as normal despite the pandemic. Despite the COVID-19 pandemic that have affected the country's economy, public health and social well-being, CRM remained crisis-proof with job security being intact.

Many exciting things are happening to the further expansion of clinical trials in Malaysia. As part of CRM's commitment to growing the capacity of our researchers in early phase research, CRM have sponsored Dr Voon Pei Jye's fellowship training in early phase oncology at Princess Margaret Cancer Centre. This sponsorship completes CRM's Phase 1 Realization Project (P1RP) which was conceived in 2016 and executed in stages to develop Malaysia's early phase clinical trial capability. We have also formalized our partnership with the National Cancer Center Japan, one of the leading oncology centres in the world. This collaboration focuses on developing Malaysia's site infrastructure and capacity building, besides providing our researchers the opportunity to participate in international collaborative research projects within the region, especially in early phase cancer genomic projects. And in the latest development, Malaysia has been identified as a site for a COVID-19 vaccine trial, involving nine public hospitals.

I would like to take this opportunity to thank everyone in the Clinical Research Malaysia for striving hard despite the pandemic. It may have been a challenging year, but the clinical research industry has adapted to many new ways to ensure continuity in operations that is now the new 'norm'. We shall continuously strive to work towards operational excellence moving forward in 2021.

Dr. Akhmal Yusof
CEO, Clinical Research Malaysia

BOARD OF DIRECTORS



YB DATO' SRI DR. ADHAM BABA
Minister of Health, Malaysia



YBHG. DATO' SERI DR. CHEN CHAW MIN
Former Secretary General,
Ministry of Health, Malaysia



YBHG. TAN SRI DATO' SERI DR. NOOR HISHAM
Director General of Health,
Ministry of Health, Malaysia



YBHG. DATUK DR. HISHAM SHAH BIN MOHD IBRAHIM
Deputy Director-General
of Health (Research & Technical
Support), Ministry of Health,
Malaysia



YBHG. DATUK DR. SHAHNAZ MURAD
Former Deputy Director General
(Research & Technical Support),
Ministry of Health, Malaysia



YBHG. PROF DATUK DR. A. RAHMAN A. JAMAL
Pro Vice Chancellor,
Universiti Kebangsaan Malaysia
(UKM)




MR. EWE KHENG HUAT
Former Executive Director
of the Pharmaceutical
Association of Malaysia
(PhAMA)



PROF DR. ABDUL RASHID ABDUL RAHMAN
Medical Director and Senior
Consultant Physician,
An Nur Specialist Hospital

ORGANISATION CHART



ABOUT CRM

VISION

To make Malaysia the preferred destination for clinical research

MISSION

- ▶ Create sustainable value proposition and conduct more CR to benefit the country
- ▶ Global trusted organisation
- ▶ Self-sufficient

CRM'S CORE SERVICES

	Complimentary Feasibility Services		Clinical Trial Budget Consultation & Management
	Development & Placement of Study Coordinators		Social Media Advertisement of Patient Recruitment in Clinical Trials
	Review of Clinical Trial Agreement [CTAs] & Non-Disclosure Agreements [NDAs]		Archiving

OUR CORE VALUES

TRANSPARENCY We practice transparency and openness in all our operations, including financial processes and budget management.	HONESTY We aspire to be honest with one another, our clients and our business partners.
ACCOUNTABILITY We set a high performance expectations and hold ourselves responsible for the quality of our work and the results we achieve as individual, as a team and as a company.	TRUSTWORTHINESS We adhere to the highest standards of professionalism and integrity and uphold the faith and confidence our clients have placed in us.

PERFORMANCE OVERVIEW

KPI SCORECARD



Figure 1: KPI Scorecard from 2012-2020

Clinical Research Malaysia was formed in 2012 with the aim to drive more sponsored research into Malaysia. By end of 2020, CRM have successfully attained its formation goals that is to create 1000 new skilled jobs, conduct 1000 sponsored research and produce a GNI of RM 578 million by 2020 (Figure 1). In 2020, a total of RM 81.6 million investment from Clinical Trial Agreements was reported through the various clinical studies that was conducted by sponsors and CROs in Malaysia. This marks a remarkable achievement in the clinical research industry in Malaysia, indicating continuous growth and income in the sector with new job creations and career opportunities in the clinical research industry.

CRM'S FINANCIAL PERFORMANCE

CRM has taken additional measures towards self-sustenance of the company since early 2019 and have been implementing measures to bridge the gap between income and expenditure. Study coordinator fee collection and CRM management fee contributed the most to CRM's income and 2020 is the first year for CRM to have successfully attained a profit surplus of over RM 600,000, despite the challenges thrown due to the global Covid-19 pandemic (Figure 2 & Figure 3).




Figure 2: CRM's financial performance in 2020

PERFORMANCE OVERVIEW





Figure 3: CRM's self-sustainability performance from 2015-2020 (Income / Expenses)

RECRUITMENT & STUDY COORDINATOR PERFORMANCE

To deliver a study conduct with speed, quality and reliability, CRM's Clinical Operations team factored in CRM's study coordinators' performance via feedback from stakeholder which are tabulated as a measurement on the overall accomplishment of study coordinators. The recruitment in a study is routinely monitored and the challenges are explored together with discussion between study team and sponsor. These led to a positive data in terms of recruitment and overall study coordinators performance in 2020 (Figure 4).



* Average percentage of recruitment achieved in 2020 in studies involving CRM study coordinators
 ** Data from CRM Customer Satisfaction Survey 2020

Figure 4: Clinical Operations Performance in 2020

SPONSORED RESEARCH IN MALAYSIA

A total of 191 sponsored research was approved by Medical Research and Ethics Committee (MREC) and Institutional Review Boards/Independent Ethics Committees (IRB/IECs) in 2020 (Figure 5). This was one of the highest numbers reported in the span of eight years, and translates sponsor/ CRO's confidence in viewing Malaysia as a reliable site for clinical research and strengthening Malaysia's position in sponsored research within the region.




Figure 5: Number of Sponsored Research from 2012-2020




Figure 6: Number of Sponsored Research in MOH sites from 2012-2020

Data sourced from MREC shows the trend has also been constant in Ministry of Health (MOH) facilities (Figure 6). More importantly, when both data are observed together, it is noted that over 60% of sponsored research are conducted in MOH facilities, showing the recognition these sites have gained owing to its performance in terms of quality and recruitment. This also means majority of patients who seek treatment in public hospitals could access to new innovative drugs through clinical research.

CLASSIFICATION OF CLINICAL TRIALS

Slightly more than half of the trials conducted in Malaysia in 2020 are interventional, out of which 66 trials (68%) involve new investigational products, 20 (20%) bioequivalence studies, 5 studies involving supplements/ herbal products, 4 medical device trials and the remaining 2 trials involving new procedures (Figure 7). Out of all interventional trials, Phase III accounts for the majority of trials followed by bioavailability/bioequivalence (BA/BE) studies, Phase II, Phase IV and Phase I (Figure 8).




Figure 7: Breakdown of studies according to intervention, 2020




Figure 8: Classification of interventional studies in Malaysia, 2020

Similar to those in developed countries, Malaysian patients have unmet medical needs and cancer and cardiovascular disease continue to be the major cause of mortality and morbidity in Malaysia. Due to the high prevalence of noncommunicable diseases in Malaysia, it provides a large patient pool for clinical trials in these therapeutic areas. In 2020, due to the need for public health to curb Covid-19 transmission, a high number of research was carried out in this area, especially observational studies in further understanding the disease burden. Hence, despite oncology trials accounted for the highest number of trials (a consistent pattern as with previous years), infections/ infectious disease research was the second highest (Figure 9). Despite the impact of Covid-19 pandemic in many of the economic and social areas in Malaysia, sponsored research continues to progress in the country with significant interest in infectious disease research.

Meanwhile, University Malaya Medical Centre recorded the highest number of sponsored trials in Malaysia for 2020 followed by Hospital Kuala Lumpur, Hospital Pulau Pinang, Sarawak General Hospital and Hospital Ampang (Figure 10).

PERFORMANCE OVERVIEW




Figure 9: Number of Sponsored Research conducted according to therapeutic area in Malaysia, 2020





Figure 10: Top sites awarded with sponsored research in Malaysia, 2020

PERFORMANCE OVERVIEW

TOP SITES ACCORDING TO THERAPEUTIC AREAS IN 2020

CRM was involved in most of the trials at Ministry of Health sites, whereby it has assisted investigators in the review of the study budget, feasibility assessments, clinical trial agreement, as well as in providing study coordinators. Below are the top clinical trial sites in 2020 in the field of oncology, infections/ infectious diseases, bioequivalence/ bioavailability studies, endocrinology diseases and cardiology/vascular diseases (Figure 11).



Note: Top sites are determined based on higher-than-average number of new sponsored studies awarded in 2020

Figure 11: Top sites in sponsored research according to therapeutic area

SITE RECRUITMENT ACHIEVEMENT IN 2020

To date, there have been 210 study sites in Malaysia that have conducted sponsored research, with 68% of them consist of public hospitals and government clinics within the Ministry of Health. Many of these sites have performed and delivered the research to the quality and standards as per the Good Clinical Practice (GCP). In 2020, some of the sites/ investigators have earned special recognition from sponsors for their recruitment achievement in global sponsored trials due to their outstanding performance in achieving recruitment target, which further elevates the positive statement on Malaysia's performance and reliability (Figure 12).




Figure 12: Site recruitment achievement in global trials, 2020

CRM SPONSORED RESEARCH AWARDS

Every year, the CRM Sponsored Research Award is given out to outstanding Principal Investigators, clinical trials sites and the industry for their contribution in sponsored research to the nation. Below are the recipients of the CRM Sponsored Research Awards 2020, which was presented by YB Dato Seri Dr Adham Baba, Minister of Health, during Clinical Trials Day 2020.



FEASIBILITY STUDY REPORT

Feasibility studies are the gateway to bringing in more clinical trials to Malaysia. It is not only a tool to assess whether a trial is possible to be conducted in Malaysia, but also a method to promote that possibility to sponsors and CROs who may not be familiar with Malaysia’s demographics, disease pattern and research sites.

CRM’s feasibility service is a complimentary service provided to sponsors and CROs who may be interested in conducting clinical trials in Malaysia. The number of full feasibilities received from 2016 to 2020 recorded a consistent growth from 98 in 2016 to 151 in 2020, in line with the growth of sponsors and CROs who have utilized CRM’s services. CRM also assisted with pre-feasibility enquiries which are also known as country level feasibility (Figure 13). Most feasibility studies received in 2020 were studies in oncology followed by haematology, infections/ infectious diseases and nephrology (Figure 14).




Figure 13: Pre-Feasibility & Full Feasibility from 2016-2020




Figure 14: Full Feasibilities received in 2020 by therapeutic area

Table 1: Top indications from the six highest feasibilities by therapeutic area received in 2020

Top 6 Full Feasibilities Received from 2015-2020 by Therapeutic Area	Top 5 Indications
Oncology	<ul style="list-style-type: none"> Non-Small Cell Lung Cancer (NSCLC) Breast Cancer Gastric/Gastroesophageal Junction Cancer Colorectal Cancer Head and Neck Cancer
Hematology	<ul style="list-style-type: none"> Lymphoma Hemophilia Leukemia Thalassemia Paroxysmal Nocturnal Hemoglobinuria
Infections and Infectious Diseases	<ul style="list-style-type: none"> Coronavirus disease (COVID-19) Ventilator acquired pneumonia Influenza A HIV Dengue
Nephrology	<ul style="list-style-type: none"> IgA Nephropathy Chronic Kidney Disease Lupus Nephritis Diabetic Kidney Disease Non-diabetic Kidney Disease
Pediatrics/Neonatology	<ul style="list-style-type: none"> Pediatric Respiratory Syncytial Virus Pediatric Diabetes Pediatric partial-onset seizures Pneumococcal Vaccine Pediatric Lymphoma
Gastroenterology	<ul style="list-style-type: none"> Ulcerative Colitis Hepatitis B Crohn's Disease Non-alcoholic steatohepatitis (NASH) Esophagitis

PERFORMANCE OVERVIEW

SPONSORS & CROS

CRM has been promoting Malaysia’s capabilities and capacities in clinical research since its establishment in June 2012 as it is essential for Malaysia to be viewed as a preferred destination for multinational sponsored research. Despite the pandemic, the growth of sponsors and CROs that have engaged with CRM has been evident in showing the growing effect Malaysia has in the global clinical trial landscape (Figure 15). These sponsors & CROs also contribute to the number of sponsored research as well as to the gross national income of the country through clinical trial contract values (Figure 16).




Figure 15: Sponsors & CROs that have engaged with CRM




Figure 16: Top contributors in number of new sponsored research by Sponsors & CROs for 2020

PERFORMANCE OVERVIEW

PLACEMENT & GROWTH OF STUDY COORDINATORS

At the establishment of CRM in 2012, it had 22 study coordinators that were placed throughout Malaysia at various sites conducting sponsored research and this number have grown to 133 in 2020 (Figure 17). CRM has expanded its provision and placement of study coordinators beyond the realm of Ministry of Health sites, to include university hospitals & private hospitals.





Figure 17: Growth of number of CRM Study Coordinators from 2016-2020

COVID-19 IN MALAYSIA

With the COVID-19 pandemic affecting Malaysia, CRM explored more virtual methods and working remotely to provide deliverance of speed, reliability, and quality in study conduct.

In Malaysia, recruitment reduced by 66% during the MCO (Movement Control Order) period in Malaysia which is similar to the global trend. However, during the CMCO (Conditional Movement Control Order) and RMCO (Recovery Movement Control Order) period, the number of studies on hold reduced drastically from 66% to 16%.

Even with the impact of COVID-19, many of the essential clinical studies resume as normal. The impact on patient recruitment is similar compared to other countries but the recovery in Malaysia is faster. Clinical trials in Malaysia operates in strict SOP guidelines and with collaboration between hospital administration, CRC, Investigators and Sponsors/CROs.

Nevertheless, the COVID-19 pandemic also offered a lot of new opportunities. CRM was involved in the COVID-19 inter-ministerial engagements as well as direct B2B discussion with various local and international sponsors and was recognized as a particularly important entity in clinical research.

As a result of these engagements, CRM was recognized as an important organization in attracting COVID-19 research in the country and was invited to present to the National Science Council, the highest council of science in Malaysia chaired by the Prime Minister. CRM was also invited to be a part of the National Vaccine Development Program and a member of Jawatankuasa Jaminan Akses Bekalan Vaksin Covid-19 (JKJAV & JKPVC) as well as the Jawatankuasa Pendaftaran, Logistic & Pembangunan in the vaccine procurement.

CRM has engaged with over 30 companies in 2020, including international organisations, that develop vaccines (Figure 1). Through science diplomacy with the Ministry of Health (MOH), Ministry of Science Technology and Innovation (MOSTI), Foreign Ministry and foreign embassies, all parties worked closely to bring in COVID-19 vaccine trials as well as procurement of the vaccines for the country.

“CRM HAS ENGAGED WITH OVER 30 COMPANIES IN 2020, INCLUDING INTERNATIONAL ORGANISATIONS, THAT DEVELOP VACCINES”



Recruitment reduced by **66%** during the MCO period in Malaysia

Number of studies on hold reduced drastically FROM **66% TO 16%** during the CMCO and RMCO period

CRM ACTIVITIES 2020

Due to the COVID-19 pandemic, CRM has explored and taken a fully virtual approach for its activities in 2020. CRM has continued to execute numerous trainings, workshops, dialogues and awareness campaign throughout the year.



CRM's GCP (Good Clinical Practice) Refresher Workshop

GCP is an international ethical and scientific quality standard for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials that are provided by International Conference of Harmonisation (ICH) GCP. This one-day GCP Refresher training is dedicated to enhancing the competence of the investigators and research team in managing the conduct of a clinical trial. CRM has carried out 3 refresher workshops throughout 2020.

CRM's Patient Recruitment and Retention Workshop

In 2020, CRM has successfully conducted 2 patient recruitment and retention workshops. This workshop aims to share best practices and explore how to maximize recruitment approaches whilst still complying with ethics & regulatory requirements.



Protocol Compliance Workshop

The Protocol Compliance workshop is an interactive workshop involving discussion on the current protocol deviation trend. The workshop is an important training to provide awareness via lessons learned to the investigators and research team. The speakers share their experience by providing PD examples and tips in handling and preventing PD. In 2020, CRM conducted 2 virtual Protocol Compliance Workshops.

Nurturing New Talents in Sponsored Research aims to develop and grow the pool of investigators in clinical research. In 2020, CRM conducted 3 virtual seminars that was participated by doctors and nurses from Hospital Sultanah Aminah [Southern Region], Hospital Raja Perempuan Zainab II, Hospital Sultanah Nur Zahirah, Hospital Tengku Ampuan Afzan and Hospital Pengajar Universiti Putra Malaysia.



CRM-MREC Good Submission Practice Training

CRM successfully conducted the very first MREC Good Submission Practice Training. The training was provided by Dr Lee Keng Yee, from MREC and representatives from over 30 sponsors and CROs attended the training. The main objective of this training is to describe and share basic best practices when making ethics application to ensure minimal error/ administrative revisions.

Preparation of Regulatory Inspection Workshop

The Preparation of Regulatory Inspection Workshop is conducted to provide knowledge to the Investigators and study team so that they are ready for the inspection by sharing experiences from regulatory perspective. CRM has successfully conducted 2 workshops in 2020.



Training to Improve Performance of Study coordinators (TIPS)

TIPS Training was conducted online to share experience and best practices amongst CRM's study coordinators and to continually sharpen their knowledge and skills in handling trial conducts at site. CRM has conducted a total of 11 TIPS Training in 8 regions, involving a total of 125 study coordinators in year 2020.

Virtual Stakeholder Dialogues




On the 17th and 21st July 2020, CRM conducted its very first virtual Industry Dialogue in 2020. Over 130 delegates (representing sponsors and CROs) participated in the 2-day webinar consisting of updates and in-depth dialogue by MREC (Medical Research and Ethics Committee), NPRA (National Pharmaceutical Regulatory Agency) and MDA (Medical Device Authority) on the new norms of clinical trial. Following the success of the virtual Industry dialogue, a 2-day Investigator Dialogue was similarly held . that featured a webinar and live dialogue session. About 50 participants from various study sites as well as representatives from ICR (Institute for Clinical Research) & MREC discussed on current remote trial practices and the shift towards a more virtual trial conduct. Lastly, CRM also organized an online discussion session on the 19th of November with our stakeholders from the industry, MREC, NPRA as well as ICR, looking into remote monitoring and current site practices.

Virtual I AM AWARE

In previous years, CRM conducted a series of 'I AM AWARE' roadshows in public hospitals, healthcare clinics and universities across the nation to drive awareness of clinical trials to the community. In the year 2020, CRM has taken a fully virtual approach in the 'I AM AWARE' campaign via CRM's own social media platforms. The virtual 'I AM AWARE' provided informative snippets about clinical trials, that are published online in both English and Bahasa Melayu languages and social media polls were also carried out to engage with the public and to further understand the current perception/ exposure they have in regard to clinical trials.



I AM AWARE SOCIAL MEDIA POLLS



CRM NEWS COVERAGE

A TRIBUTE TO OUR HEROES ON INTERNATIONAL CLINICAL TRIALS DAY



KUALA LUMPUR, 20 May 2020 — International Clinical Trials Day is celebrated around the world on May 20 every year to recognize the people who conduct clinical trials as well as the volunteers and patients who participate in it. Clinical Trials Day has always been part of CRM's ongoing effort in creating awareness among the general public, patients as well as healthcare professionals that contribute to the development of better innovative treatments in the medical field. The CRM Sponsored Research Awards has been a significant part of the nation's Clinical Trials Day program organized by CRM annually since 2017. Through this awards presentation, CRM tributes outstanding accomplishments and contribution by the Sponsors, CROs, Trial sites and Investigators in elevating sponsored research in Malaysia.

MALAYSIA SENDS ITS MEDICAL ONCOLOGIST TO BE TRAINED IN ONE OF THE TOP CANCER RESEARCH CENTERS IN THE WORLD



KUALA LUMPUR, 28 July 2020 — MOH through CRM sponsored Dr. Voon Pei Jye, Medical Oncologist at Sarawak General Hospital, for a Clinical Fellowship Training at Princess Margaret Cancer Centre which is affiliated with the University of Toronto, Canada. Princess Margaret Cancer Centre is one of the top 5 and largest cancer research centers in the world and focuses on all three areas of research: basic, translational, and clinical research. Dr. Voon is posted at the Department of Medicine, Division of Medical Oncology in Phase 1 for a period of 13 months starting 1st September 2020.

MALAYSIA PARTNERS WITH JAPAN'S TOP ONCOLOGY HOSPITAL TO FOCUS ON ONCOLOGY DRUG DEVELOPMENT



KUALA LUMPUR & TOKYO, JAPAN, 30 October 2020 — Clinical Research Malaysia inked a MoU with the National Cancer Center Hospital to develop Malaysia's capabilities and capacities in oncology clinical research. The MoU with NCCH (National Cancer Center Hospital) spells out collaboration in the areas of cancer research that includes infrastructure development, training opportunities in clinical research, participation in rare cancer clinical trial, networking opportunities as well as visits/ attachments by research experts from both countries. This will further pave the way for better Malaysia-Japan collaborations in advancing drug development.

PUBLICATIONS

Six articles featuring topics from feasibility rejection reasons to important clauses in clinical trial agreement was published in 2020. Having a multiprong approach in promoting Malaysia's clinical research capabilities is essential in engaging with the global community and article publication is one way in disseminating these messages to international readers in the clinical research industry. Do head to <https://clinicalresearch.my/articles/> to access all of CRM's Articles.

FEB
2020



Ensuring Effective Financial Management in Sponsored Research in Malaysia (20 February) – Journal for Clinical Studies

Link: <https://clinicalresearch.my/ensuring-effective-financial-management-in-sponsored-research-in-malaysia/>

APR
2020



Establishing Clear Procedures and Improving Start-up Timeline in Malaysia's Clinical Research Ecosystem (17 April) – Journal for Clinical Studies

Link: <https://clinicalresearch.my/establishing-clear-procedures-and-improving-start-up-timeline-in-malysias-clinical-research-ecosystem/>

SEP
2020



To Participate or Not Participate: Why Do Investigators Reject a Clinical Research? (8 September) – Journal for Clinical Studies

Link: <https://clinicalresearch.my/wp-content/uploads/2020/12/To-Participate-or-Not-Participate-1.pdf>

OCT
2020



Impact of Strategic Alliance in Clinical trial Sites in Malaysia: The ICR-CRM-IQVIA research network collaboration experience (1 October) – Applied Clinical Trials

Link: <https://www.appliedclinicaltrials.com/view/the-icr-crm-iqv-ia-research-network-collaboration-experience>

OCT
2020



What does it Take to have a Good Experience of Recruitment in Clinical Research: Malaysia (16 October) – Journal for Clinical Studies

Link: <https://www.jforcs.com/what-does-it-take-to-have-a-good-experience-of-recruitment-in-clinical-research-malaysia/>

DEC
2020



Important Clauses in a Clinical Trial Agreement (31 December) – CLJ Bulletin

Link: <https://clinicalresearch.my/wp-content/uploads/2021/01/Important-Clauses-in-Clinical-Trial-Agreement.pdf>

PATIENT RECRUITMENT ADVERTISEMENT SERVICE

Increase the reach of your advertisement through
CRM social media platforms



DURATION OF
ADVERTISEMENT:
Two weeks



TARGETED REACH:
**> 500,000
people**

For more details, please contact: aina.farhana@clinicalresearch.my

To submit, please provide the final advertisement design and proof of Ethics Committee approval.

CRM IN PHOTOS



Meeting with Mr Miyasaka, Head of Welfare Attaché
from the Embassy of Japan

JANUARY 7



Meeting with Geneaid Biomed (Taiwan)

JANUARY 10



Meeting with SunMed Clinical Research Centre team,
researchers from Cambridge University and NPRA
senior officers.

JANUARY 15



Visit by delegation from Indonesian Ministry of Health
and the National Institute of Health Research and
Development (NIHRD)

JANUARY 21



Meeting with Dr Hishamshah Mohd Ibrahim

JANUARY 23



Meeting with Dr Goh Siew Lee & Ms. Serena Chan from
Syneos Health

JANUARY 23



Meeting with Medi Radio Malaysia and Universiti
Putra Malaysia

FEBRUARY 3



Asia Pacific Economic Cooperation

FEBRUARY 21



Site Visit to National Cancer Institute and HKL by the team from National Cancer Center Japan

FEBRUARY 24



Meeting with Malaysia Bioeconomy Development

FEBRUARY 24



Info Day Medical University Malaysia

FEBRUARY 26



Meeting with Malaysian Health Diplomacy Foundation and Saora Industries

JUNE 12



Meeting with Tan Sri Dato Lim Yew Loong and Sinopharm representatives

JUNE 12



Presentation on Malaysia's clinical research ecosystem to the National Science Council at Parliament

JULY 15



Meeting with Dr Khor Swee Kheng (Health Systems/Policies/Health practitioner)

AUGUST 6



Meeting with Cytonex Sdn Bhd

AUGUST 19



Meeting with Embassy of Russian Federation in Malaysia

26 AUGUST



Dato' Dr Goh Pik Pin Retirement

28 AUGUST



Meeting with Deputy Director of Life Sciences & Medtech Division of MIDA

SEPTEMBER 2



Virtual Nurturing New Talent in Sponsored Research- East Coast

SEPTEMBER 10



Meeting with Mr Isaac Lim and Ms Alicia Tee from Singapore High Commission

SEPTEMBER 11



Meeting with Meluha Life Sciences

SEPTEMBER 17



Courtesy visit by Deputy Trade Representative of Russian Federation in Malaysia

SEPTEMBER 18



Provisionally Registered Pharmacist (PRP) attachment

SEPTEMBER 22



Meeting with Tri-G Technologies Sdn Bhd

SEPTEMBER 25



Meeting with Navamed

SEPTEMBER 30



Meeting with GHHS Healthcare

OCTOBER 1



Meeting with Future CytoHealth

OCTOBER 6



Client Engagement Meeting with Janssen

OCTOBER 7



Awareness Briefing Session for ISO 37001:2016 Anti-Bribery Management System

OCTOBER 22



CRM 4th Company Meeting 2020

DECEMBER 1



Meeting with Datuk P.S. Jaya, Project Director of MyEG

DECEMBER 9

WHAT'S NEXT IN 2021

Moving forward, CRM will continue striving towards Operational Excellence in all departments by embracing teamwork, empowerment, and communication by further escalating its endeavours on the 4 key strategies. New business opportunities that facilitate clinical research operations at site are to be explored, including home study visits, study recruitment advertising and destruction of investigational products. Continuing its aim in becoming a global trusted Research Management Organization, CRM will be embarking on ISO 37001:2016 Anti-Bribery Management System. The company will also be undergoing its re-certification of ISO 9001:2015 Quality Management System to ensure deliverance of speed, quality, and reliability in the services it provides.



Do you or someone you know have *medical conditions?*


such as cancer, diabetes, heart disease and others

Visit the link below to find a clinical trial near you
www.clinicalresearch.my/fact

REGISTER FOR CLINICAL TRIAL VIA FACT WEBSITE



PARTICIPATING IN A CLINICAL TRIAL – What you need to know



For more information, please send us a message via Whatapp at
016-320 0376 or email to **contact@clinicalresearch.my**



WWW.CLINICALRESEARCH.MY



Your Global Solutions in One Nation

D-26-06, Menara Suezcap 1, KL Gateway, No. 2 Jalan Kerinchi,
Gerbang Kerinchi Lestari, 59200 Kuala Lumpur, Malaysia.

T: +603-7931 5566 | **F:** +603-7931 9940 | **E:** contact@clinicalresearch.my

© 2021 Clinical Research Malaysia. All Rights Reserved.



CERTIFIED TO ISO 9001:2015
CERT NO.: QMS 03360



CERTIFIED TO ISO 9001:2015
CERT NO.: QMS 03360